Prospective strategies to delay the evolution of anti-malarial drug resistance: Weighing the uncertainty

Malaria Journal

Volumn 9, Issue 1, 2010, Pages

  Smith, David L ^a   Klein, Eili Y ^b,c   McKenzie, F Ellis ^d   Laxminarayan, Ramanan ^b,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b RESOURCES FOR THE FUTURE   (United States)

^c PRINCETON UNIVERSITY   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ DERIVATIVE; ANTIMALARIAL AGENT;

ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; MALARIA; PHENOTYPE; THERAPY; BIOLOGICAL MODEL; DRUG COMBINATION; DRUG EFFECT; GENETICS; PARASITOLOGY; PLASMODIUM; STATISTICS; TIME; UNCERTAINTY;

ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MALARIA; MODELS, BIOLOGICAL; PLASMODIUM; STOCHASTIC PROCESSES; TIME FACTORS; UNCERTAINTY;

EID: 77954788735     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-217     Document Type: Article

References (27)

1. Defining the global spatial limits of malaria transmission in 2005. CA Guerra RW Snow SI Hay, Adv Parasitol 2006 62 157 179 10.1016/S0065-308X(05) 62005-2 16647970
2. A world malaria map: Plasmodium falciparum endemicity in 2007. SI Hay CA Guerra PW Gething AP Patil AJ Tatem AM Noor CW Kabaria BH Manh IR Elyazar S Brooker DL Smith RA Moyeed RW Snow, PLoS Med 2009 6 1000048 19323591
3. The role of anti-malarial drugs in eliminating malaria. NJ White, Malar J 2008 7 Suppl 1 8 10.1186/1475-2875-7-S1-S8 19091042
4. The past, present and future of childhood malaria mortality in Africa. RW Snow JF Trape K Marsh, Trends Parasitol 2001 17 593 597 10.1016/S1471-4922(01) 02031-1 11756044
5. Antimalarial drug resistance and combination chemotherapy. N White, Philos Trans R Soc Lond B Biol Sci 1999 354 739 749 10.1098/rstb.1999.0426 10365399
6. Do we need to put society first? The potential for tragedy in antimicrobial resistance. KR Foster H Grundmann, PLoS Med 2006 3 29 10.1371/journal.pmed.0030029 16398572
7. Evaluating treatment protocols to prevent antibiotic resistance. S Bonhoeffer M Lipsitch BR Levin, Proc Natl Acad Sci USA 1997 94 12106 12111 10.1073/pnas.94.22.12106 9342370
8. Benefits of using multiple first-line therapies against malaria. MF Boni DL Smith R Laxminarayan, Proc Natl Acad Sci USA 2008 105 14216 14221 10.1073/pnas.0804628105 18780786
9. Mutations of bacteria from virus sensitivity to virus resistance. SE Luria M Delbruck, Genetics 1943 28 491 511 17247100
10. The role of evolution in the emergence of infectious diseases. R Antia RR Regoes JC Koella CT Bergstrom, Nature 2003 426 658 661 10.1038/nature02104 14668863
11. The role of compensatory mutations in the emergence of drug resistance. A Handel RR Regoes R Antia, PLoS Comput Biol 2006 2 137 10.1371/journal.pcbi. 0020137 17040124
12. The biological cost of mutational antibiotic resistance: any practical conclusions? DI Andersson, Curr Opin Microbiol 2006 9 461 465 10.1016/j.mib.2006.07.002 16890008
13. The biological cost of antibiotic resistance. DI Andersson BR Levin, Curr Opin Microbiol 1999 2 489 493 10.1016/S1369-5274(99)00005-3 10508723
14. Return of chloroquine antimalarial efficacy in Malawi. MK Laufer PC Thesing ND Eddington R Masonga FK Dzinjalamala SL Takala TE Taylor CV Plowe, N Engl J Med 2006 355 1959 1966 10.1056/NEJMoa062032 17093247
15. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. JG Kublin JF Cortese EM Njunju RA Mukadam JJ Wirima PN Kazembe AA Djimde B Kouriba TE Taylor CV Plowe, J Infect Dis 2003 187 1870 1875 10.1086/375419 12792863
16. Delaying antimalarial drug resistance with combination chemotherapy. NJ White, Parassitologia 1999 41 301 308 10697872
17. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. CA Guerra PW Gikandi AJ Tatem AM Noor DL Smith SI Hay RW Snow, PLoS Med 2008 5 38 10.1371/journal.pmed.0050038 18303939
18. Estimation for discrete time branching processes with application to epidemics. N Becker, Biometrics 1977 33 515 522 10.2307/2529366 911971
19. The entomological inoculation rate and Plasmodium falciparum infection in African children. DL Smith J Dushoff RW Snow SI Hay, Nature 2005 438 492 495 10.1038/nature04024 16306991
20. Revisiting the basic reproductive number for malaria and its implications for malaria control. DL Smith FE McKenzie RW Snow SI Hay, PLoS Biol 2007 5 42 10.1371/journal.pbio.0050042 17311470
21. The dynamics of mutations associated with anti-malarial drug resistance in Plasmodium falciparum. AA Escalante DL Smith Y Kim, Trends Parasitol 2009 25 557 563 10.1016/j.pt.2009.09.008 19864183
22. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. SI Hay EA Okiro PW Gething AP Patil AJ Tatem CA Guerra RW Snow, PLoS Med 2010 7 1000290 10.1371/journal.pmed.1000290 20563310
23. Mutation rates in the dihydrofolate reductase gene of Plasmodium falciparum. S Paget-McNicol A Saul, Parasitology 2001 122 497 505 10.1017/S0031182001007739 11393822
24. A global subsidy: key to affordable drugs for malaria? R Laxminarayan H Gelband, Health Aff (Millwood) 2009 28 949 961 10.1377/hlthaff.28.4.949 19597193
25. Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. A Afonso P Hunt S Cheesman AC Alves CV Cunha V do Rosario P Cravo, Antimicrob Agents Chemother 2006 50 480 489 10.1128/AAC.50.2.480-489.2006 16436700
26. Artemisinin-resistant malaria in Asia. H Noedl D Socheat W Satimai, N Engl J Med 2009 361 540 541 10.1056/NEJMc0900231 19641219
27. Qinghaosu (artemisinin): the price of success. NJ White, Science 2008 320 330 334 10.1126/science.1155165 18420924